FDA re­ject­ed Out­look Ther­a­peu­tic­s' Lu­cen­tis ri­val, and the com­pa­ny's stock plunged

The FDA has re­ject­ed Out­look Ther­a­peu­tics’ oph­thalmic for­mu­la­tion of be­va­cizum­ab for wet AMD, an eye dis­or­der that can cause blurred vi­sion or blind spots. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER